Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24334191,total chromatographic run time,The total chromatographic run time was 2.0 min and calibration curves were linear over the concentration range of 0.10-20.00 ng/mL for Olanzapine and 0.50-50.00 ng/mL for Fluoxetine.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),min,2.0,3333,DB00472,Fluoxetine
≥,24334191,recoveries,The recoveries obtained for the Olanzapine and its IS was ≥87% and Fluoxetine and its IS was ≥91%.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),%,87,3334,DB00472,Fluoxetine
≥,24334191,recoveries,The recoveries obtained for the Olanzapine and its IS was ≥87% and Fluoxetine and its IS was ≥91%.,Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24334191/),%,91,3335,DB00472,Fluoxetine
,34345606,m/z,"To quantify the FLX and FLX-d5, the parent-to-daughter ion transition of m/z of 310.0/44.1 and 315.0/44.0 was used, respectively.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),,310.0,3887,DB00472,Fluoxetine
,34345606,m/z,"To quantify the FLX and FLX-d5, the parent-to-daughter ion transition of m/z of 310.0/44.1 and 315.0/44.0 was used, respectively.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),,44.1,3888,DB00472,Fluoxetine
,34345606,m/z,"To quantify the FLX and FLX-d5, the parent-to-daughter ion transition of m/z of 310.0/44.1 and 315.0/44.0 was used, respectively.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),,315.0,3889,DB00472,Fluoxetine
,34345606,m/z,"To quantify the FLX and FLX-d5, the parent-to-daughter ion transition of m/z of 310.0/44.1 and 315.0/44.0 was used, respectively.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),,44.0,3890,DB00472,Fluoxetine
,34345606,recoveries,The method demonstrated a linear active limit of 0.20-30 ng/ml with recoveries ranging from 63.04% to 79.39% for quality control samples and 61.25% for IS samples.,Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),%,63.04,3891,DB00472,Fluoxetine
,34345606,recoveries,The method demonstrated a linear active limit of 0.20-30 ng/ml with recoveries ranging from 63.04% to 79.39% for quality control samples and 61.25% for IS samples.,Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),%,79.39,3892,DB00472,Fluoxetine
,34345606,recoveries,The method demonstrated a linear active limit of 0.20-30 ng/ml with recoveries ranging from 63.04% to 79.39% for quality control samples and 61.25% for IS samples.,Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),%,61.25,3893,DB00472,Fluoxetine
,34345606,minimum threshold,"Due to the high inconsistency of the FLX concentration data, the minimum threshold of the assay was kept at 0.20 ng/ml.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),[ng] / [ml],0.20,3894,DB00472,Fluoxetine
,34345606,flow rate,"The flow rate was maintained at 500 μL/min, and the time for sample analysis for each injection was 3.5 min.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),[μl] / [min],500,3895,DB00472,Fluoxetine
,34345606,time for,"The flow rate was maintained at 500 μL/min, and the time for sample analysis for each injection was 3.5 min.",Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34345606/),min,3.5,3896,DB00472,Fluoxetine
,24688155,Cmax,"In the 2 periods of treatment, the mean Cmax of omeprazole was 730.8 ng/mL (omeprazole monotherapy) and 1725.5 ng/mL (combination treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [ml],730.8,5615,DB00472,Fluoxetine
,24688155,Cmax,"In the 2 periods of treatment, the mean Cmax of omeprazole was 730.8 ng/mL (omeprazole monotherapy) and 1725.5 ng/mL (combination treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [ml],1725.5,5616,DB00472,Fluoxetine
,24688155,AUC0-∞,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],1453.3,5617,DB00472,Fluoxetine
,24688155,AUC0-∞,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],5072.5,5618,DB00472,Fluoxetine
,24688155,AUC0-t,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],1465.0,5619,DB00472,Fluoxetine
,24688155,AUC0-t,"The observed AUC0-∞ was 1453.3 and 5072.5 ng/mL/h and AUC0-t was 1465.0 and 5185.3 ng/mL/h, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),[ng] / [h·ml],5185.3,5620,DB00472,Fluoxetine
,24688155,Tmax,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.30,5621,DB00472,Fluoxetine
,24688155,Tmax,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.63,5622,DB00472,Fluoxetine
,24688155,elimination rate constant,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),1/[hr],0.753,5623,DB00472,Fluoxetine
,24688155,elimination rate constant,The Tmax was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr(-1).,Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),1/[hr],0.482,5624,DB00472,Fluoxetine
,24688155,t½,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,0.96,5625,DB00472,Fluoxetine
,24688155,t½,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,1.47,5626,DB00472,Fluoxetine
,24688155,mean residence time,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,2.33,5627,DB00472,Fluoxetine
,24688155,mean residence time,"The t½ was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 3.35 hours, respectively.",Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688155/),h,3.35,5628,DB00472,Fluoxetine
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,387,7523,DB00472,Fluoxetine
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,99.2,7524,DB00472,Fluoxetine
,32557079,AUC0-∞R,The maternal pharmacokinetics of fexofenadine was enantioselective (AUC0-∞R-(+)/S-(-) ~ 1.5) in both control and interaction groups.,Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),,1.5,7873,DB00472,Fluoxetine
,32557079,AUC0-∞,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[h·ng] / [ml],267.7,7874,DB00472,Fluoxetine
,32557079,AUC0-∞,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[h·ng] / [ml],376.1,7875,DB00472,Fluoxetine
,32557079,oral total clearance,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[l] / [h],105.1,7876,DB00472,Fluoxetine
,32557079,oral total clearance,"Fluoxetine increased AUC0-∞ (267.7 vs 376.1 ng.h/mL) and decreased oral total clearance (105.1 vs 74.4 L/h) only of S-(-)-fexofenadine, whereas the renal clearance were reduced for both enantiomers, suggesting that the intestinal P-gp-mediated transport of S-(-)-fexofenadine is influenced by fluoxetine to a greater extent that the R-(+)-fexofenadine.",Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557079/),[l] / [h],74.4,7877,DB00472,Fluoxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB00472,Fluoxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB00472,Fluoxetine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB00472,Fluoxetine
,17803058,mlz,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,330.0,14930,DB00472,Fluoxetine
,17803058,mlz,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,192.0,14931,DB00472,Fluoxetine
,17803058,m/ z,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,310,14932,DB00472,Fluoxetine
,17803058,m/ z,"The ionization was optimized using ESI(+) and selectivity was achieved by MS-MS analysis, mlz 330.0-->192.0 and m/ z 310-->148 for paroxetine and fluoxetine, respectively.",Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),,148,14933,DB00472,Fluoxetine
,17803058,total run time,The method has a total run time of 1.5 min and was linear over a working range of 0.05-20 ng/mL and the lower limit of quantification was 0.05 ng/ mL.,Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803058/),min,1.5,14934,DB00472,Fluoxetine
,16528137,Trough concentrations,"Trough concentrations of milnacipran were 66 and 65 ng/ml before and after the fluoxetine administration period, respectively.",Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528137/),[ng] / [ml],66,17062,DB00472,Fluoxetine
,16528137,Trough concentrations,"Trough concentrations of milnacipran were 66 and 65 ng/ml before and after the fluoxetine administration period, respectively.",Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528137/),[ng] / [ml],65,17063,DB00472,Fluoxetine
,16528137,Cmax,Cmax values were 226 and 248 ng/ml.,Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528137/),[ng] / [ml],226,17064,DB00472,Fluoxetine
,16528137,Cmax,Cmax values were 226 and 248 ng/ml.,Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528137/),[ng] / [ml],248,17065,DB00472,Fluoxetine
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB00472,Fluoxetine
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB00472,Fluoxetine
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB00472,Fluoxetine
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB00472,Fluoxetine
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB00472,Fluoxetine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,16.4,26950,DB00472,Fluoxetine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,12.3,26951,DB00472,Fluoxetine
,8216694,half-life,"Levels peaked within 30 minutes, and elimination of CLZ from brain and CLZ or NOR from blood was very rapid (half-life = 1.5 to 1.6 hours).",Tissue concentrations of clozapine and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216694/),h,1.5 to 1.6,27568,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB00472,Fluoxetine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB00472,Fluoxetine
,22282085,overall recovery,"The overall recovery for agomelatine and fluoxetine was 67.10% and 72.96%, respectively.",Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282085/),%,67.10,31458,DB00472,Fluoxetine
,22282085,overall recovery,"The overall recovery for agomelatine and fluoxetine was 67.10% and 72.96%, respectively.",Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282085/),%,72.96,31459,DB00472,Fluoxetine
,22490230,k(inact),"The inactivation kinetic parameter, k(inact), was most consistent across systems tested for clarithromycin, verapamil, and troleandomycin, with a high k(inact) of 0.91 min(-1) observed for mibefradil in HepaRG cells.",Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),1/[min],0.91,32837,DB00472,Fluoxetine
,22490230,apparent K(I),The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5.4-17.7 μM) to 6-fold for verapamil (1.9-12.6 μM).,Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),μM,5.4-17.7,32838,DB00472,Fluoxetine
,22490230,apparent K(I),The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5.4-17.7 μM) to 6-fold for verapamil (1.9-12.6 μM).,Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),μM,1.9-12.6,32839,DB00472,Fluoxetine
,15665745,recovery,Average recovery was about 100% for both substances.,A sensitive HPLC method for the determination of fluoxetine and norfluoxetine in human plasma with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665745/),%,100,36868,DB00472,Fluoxetine
,1876622,half-life,"Fluoxetine distinguishes itself in that its half-life is 2 to 3 days, whereas the mean half-life of buproprion and the tricyclics are 10 to 14 hours.",Treatment of depression. New pharmacologic approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876622/),d,2 to 3,37731,DB00472,Fluoxetine
,1876622,half-life,"Fluoxetine distinguishes itself in that its half-life is 2 to 3 days, whereas the mean half-life of buproprion and the tricyclics are 10 to 14 hours.",Treatment of depression. New pharmacologic approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1876622/),h,10 to 14,37732,DB00472,Fluoxetine
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39866,DB00472,Fluoxetine
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39867,DB00472,Fluoxetine
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39868,DB00472,Fluoxetine
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39869,DB00472,Fluoxetine
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],4.3,39870,DB00472,Fluoxetine
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],0.4,39871,DB00472,Fluoxetine
,15886723,brain levels,"At 5 weeks, the racemate, 80 and 120 mg/day R-fluoxetine groups had mean brain levels of 25.5, 34.9, and 41.4 microM, respectively.",A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886723/),,34.9,43059,DB00472,Fluoxetine
,15886723,brain levels,"At 5 weeks, the racemate, 80 and 120 mg/day R-fluoxetine groups had mean brain levels of 25.5, 34.9, and 41.4 microM, respectively.",A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886723/),,41.4,43060,DB00472,Fluoxetine
,7992822,elimination half-lives,"The selective serotonin reuptake inhibitors (SSRIs)--paroxetine, sertraline, and fluvoxamine--have elimination half-lives of 15-26 hours.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,15-26,43464,DB00472,Fluoxetine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-6,43465,DB00472,Fluoxetine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-16,43466,DB00472,Fluoxetine
,7992822,half-lives,"Venlafaxine and nefazodone have short half-lives, 2-5 hours, and are dosed > or = 2 times daily.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,2-5,43467,DB00472,Fluoxetine
,10917403,half-life,"Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies.","Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10917403/),d,7 to 15,53440,DB00472,Fluoxetine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00472,Fluoxetine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00472,Fluoxetine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00472,Fluoxetine
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],5.5,61646,DB00472,Fluoxetine
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],171.9,61647,DB00472,Fluoxetine
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],13.1,61648,DB00472,Fluoxetine
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],3075.2,61649,DB00472,Fluoxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,1 and 4,62758,DB00472,Fluoxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,7 and 15,62759,DB00472,Fluoxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,21,62760,DB00472,Fluoxetine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,36,62761,DB00472,Fluoxetine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,11,63198,DB00472,Fluoxetine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,83,63199,DB00472,Fluoxetine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,24,63200,DB00472,Fluoxetine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,20,63201,DB00472,Fluoxetine
,7946933,liver:water partition ratios,"4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml-1 and 72 ng ml-1, respectively, after correction for liver:water partition ratios in the range of 12-14.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),,12-14,63202,DB00472,Fluoxetine
,7946933,Ki,"5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,0.046,63203,DB00472,Fluoxetine
,7946933,Ki,Quinidine was a weak inhibitor (Ki = 626 microM).,"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,626,63204,DB00472,Fluoxetine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0024,63727,DB00472,Fluoxetine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0019,63728,DB00472,Fluoxetine
,33825113,placental transfer rates,The placental transfer rates were similar between (S)-(-)- and (R)-(+)-fexofenadine in both Control (0.0024 vs 0.0019 min-1) and Interaction (0.0019 vs 0.0021 min-1) periods.,Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825113/),1/[min],0.0021,63729,DB00472,Fluoxetine
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.037,66325,DB00472,Fluoxetine
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.34,66326,DB00472,Fluoxetine
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.28,66327,DB00472,Fluoxetine
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,2.05,66328,DB00472,Fluoxetine
,8666216,steady-state plasma concentrations,"The mean +/- standard deviation steady-state plasma concentrations of the sum of fluoxetine plus its metabolite norfluoxetine for patients completing 8 weeks (N = 6, both groups) were comparable for the patients undergoing hemodialysis (253 +/- 61 ng/ml) and those with normal kidney function (218 +/- 122 ng/ml; t = 1.5, df = 70, p > 0.13).",Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666216/),[ng] / [ml],253,67599,DB00472,Fluoxetine
,8666216,steady-state plasma concentrations,"The mean +/- standard deviation steady-state plasma concentrations of the sum of fluoxetine plus its metabolite norfluoxetine for patients completing 8 weeks (N = 6, both groups) were comparable for the patients undergoing hemodialysis (253 +/- 61 ng/ml) and those with normal kidney function (218 +/- 122 ng/ml; t = 1.5, df = 70, p > 0.13).",Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666216/),[ng] / [ml],218,67600,DB00472,Fluoxetine
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00472,Fluoxetine
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00472,Fluoxetine
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00472,Fluoxetine
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00472,Fluoxetine
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00472,Fluoxetine
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00472,Fluoxetine
,25863117,Cmax,"The Cmax of FX after the transdermal administration of the optimized patch formulation in rats was 52.38 ng/ml, and plasma concentration of FX was maintained for 36 h.",Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: In vitro and in vivo evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25863117/),[ng] / [ml],52.38,68946,DB00472,Fluoxetine
,25863117,Css,"Moreover, the predicted human Css (55.79 ng/ml) and Cmax (27.35 ng/ml) were in good agreement with the reported plasma levels (15-55 ng/ml) of oral FX in clinical applications.",Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: In vitro and in vivo evaluations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25863117/),[ng] / [ml],55.79,68947,DB00472,Fluoxetine
,25863117,Cmax,"Moreover, the predicted human Css (55.79 ng/ml) and Cmax (27.35 ng/ml) were in good agreement with the reported plasma levels (15-55 ng/ml) of oral FX in clinical applications.",Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: In vitro and in vivo evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25863117/),[ng] / [ml],27.35,68948,DB00472,Fluoxetine
,16229112,t(max),Average t(max) was 5.4 h for fluoxetine and 71-80 h for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),h,5.4,73150,DB00472,Fluoxetine
,16229112,t(max),Average t(max) was 5.4 h for fluoxetine and 71-80 h for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),h,71-80,73151,DB00472,Fluoxetine
,16229112,peak concentration,The peak concentration was on average 14 ng/ml for fluoxetine and 10.5 ng/ml for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),[ng] / [ml],14,73152,DB00472,Fluoxetine
,16229112,peak concentration,The peak concentration was on average 14 ng/ml for fluoxetine and 10.5 ng/ml for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),[ng] / [ml],10.5,73153,DB00472,Fluoxetine
,16229112,Half-life,Half-life was on average 48-50 h for fluoxetine and 130-138 h for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),h,48-50,73154,DB00472,Fluoxetine
,16229112,Half-life,Half-life was on average 48-50 h for fluoxetine and 130-138 h for norfluoxetine.,Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),h,130-138,73155,DB00472,Fluoxetine
,16229112,AUC infinity,"AUC infinity for fluoxetine and norfluoxetine were on average 790 and 2800 ng x ml(-1) x h, respectively.",Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),[h·ng] / [ml],790,73156,DB00472,Fluoxetine
,16229112,AUC infinity,"AUC infinity for fluoxetine and norfluoxetine were on average 790 and 2800 ng x ml(-1) x h, respectively.",Bioequivalence study of fluoxetine hydrochloride in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16229112/),[h·ng] / [ml],2800,73157,DB00472,Fluoxetine
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB00472,Fluoxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB00472,Fluoxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB00472,Fluoxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB00472,Fluoxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB00472,Fluoxetine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB00472,Fluoxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB00472,Fluoxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB00472,Fluoxetine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB00472,Fluoxetine
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],44.02,84654,DB00472,Fluoxetine
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],62.72,84655,DB00472,Fluoxetine
,16770757,Cmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.15,84656,DB00472,Fluoxetine
,16770757,tmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.06,84657,DB00472,Fluoxetine
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],312.61,84658,DB00472,Fluoxetine
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],590.62,84659,DB00472,Fluoxetine
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,5.52,84660,DB00472,Fluoxetine
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,8.47,84661,DB00472,Fluoxetine
,19517423,flow-rate,"The HPLC separation of the analytes was performed on a Zorbax SB-C(18), 50 x 4.6 mm, 5 microm column, using a isocratic elution program using a mobile phase consisting of HPLC-grade methanol: 5 mm ammonium acetate (80:20 v/v) at a flow-rate of 1.0 mL/min with a total runtime of 3.0 min.",Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517423/),[ml] / [min],1.0,85413,DB00472,Fluoxetine
,19517423,total runtime,"The HPLC separation of the analytes was performed on a Zorbax SB-C(18), 50 x 4.6 mm, 5 microm column, using a isocratic elution program using a mobile phase consisting of HPLC-grade methanol: 5 mm ammonium acetate (80:20 v/v) at a flow-rate of 1.0 mL/min with a total runtime of 3.0 min.",Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517423/),min,3.0,85414,DB00472,Fluoxetine
,9090339,brain-to-plasma ratio at steady state,The mean brain-to-plasma ratio at steady state was 24 to 1.,19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9090339/),,24 to 1,86089,DB00472,Fluoxetine
,9090339,T1,Brain fluvoxamine T1 values from 140 to 230 msec were observed.,19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9090339/),ms,140 to 230,86090,DB00472,Fluoxetine
,8085287,plasma IP,"Initial plasma IP level was 2260 ng/ml, whole blood total cyclosporine (T-CsA) concentration was 1,800 ng/ml and that of specific cyclosporine (Sp-CsA), 714 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],714,90235,DB00472,Fluoxetine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],232,90236,DB00472,Fluoxetine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],401,90237,DB00472,Fluoxetine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],96,90238,DB00472,Fluoxetine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,43.4,90239,DB00472,Fluoxetine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,70.1,90240,DB00472,Fluoxetine
,21095492,C(max),"In extensive metabolizers, the mean (SD) C(max) for fluoxetine with the test formulation was 11.786 (3.459) ng/mL and T(max) was 5.48 (2.06) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),[ng] / [ml],11.786,94414,DB00472,Fluoxetine
,21095492,T(max),"In extensive metabolizers, the mean (SD) C(max) for fluoxetine with the test formulation was 11.786 (3.459) ng/mL and T(max) was 5.48 (2.06) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,5.48,94415,DB00472,Fluoxetine
,21095492,t(½),"The t(½) values with the test and reference formulations were 30.86 (7.61) and 30.96 (6.91) hours, respectively.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,30.86,94416,DB00472,Fluoxetine
,21095492,t(½),"The t(½) values with the test and reference formulations were 30.86 (7.61) and 30.96 (6.91) hours, respectively.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,30.96,94417,DB00472,Fluoxetine
,21095492,C(max),"For norfluoxetine, mean C(max) with the test formulation was 14.177 (4.957) ng/mL and T(max) was 58.48 (31.67) hours; the corresponding values for the reference formulation were 13.828 (4.838) ng/mL and 57.91 (25.75) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),[ng] / [ml],14.177,94418,DB00472,Fluoxetine
,21095492,T(max),"For norfluoxetine, mean C(max) with the test formulation was 14.177 (4.957) ng/mL and T(max) was 58.48 (31.67) hours; the corresponding values for the reference formulation were 13.828 (4.838) ng/mL and 57.91 (25.75) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,58.48,94419,DB00472,Fluoxetine
,21095492,T(max),"For norfluoxetine, mean C(max) with the test formulation was 14.177 (4.957) ng/mL and T(max) was 58.48 (31.67) hours; the corresponding values for the reference formulation were 13.828 (4.838) ng/mL and 57.91 (25.75) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),[ng] / [ml],13.828,94420,DB00472,Fluoxetine
,21095492,T(max),"For norfluoxetine, mean C(max) with the test formulation was 14.177 (4.957) ng/mL and T(max) was 58.48 (31.67) hours; the corresponding values for the reference formulation were 13.828 (4.838) ng/mL and 57.91 (25.75) hours.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,57.91,94421,DB00472,Fluoxetine
,21095492,t(½),"The t(½) values with the test and reference formulations were 130.91 (42.04) and 128.79 (52.72) hours, respectively.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,130.91,94422,DB00472,Fluoxetine
,21095492,t(½),"The t(½) values with the test and reference formulations were 130.91 (42.04) and 128.79 (52.72) hours, respectively.","Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21095492/),h,128.79,94423,DB00472,Fluoxetine
,9824228,recoveries,"Mean recoveries following solid-phase extraction at concentrations of 5.0, 20 and 100 ng/ml were 91% (fluoxetine) and 87% (norfluoxetine).","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),%,91,94805,DB00472,Fluoxetine
,9824228,recoveries,"Mean recoveries following solid-phase extraction at concentrations of 5.0, 20 and 100 ng/ml were 91% (fluoxetine) and 87% (norfluoxetine).","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),%,87,94806,DB00472,Fluoxetine
,9824228,Cmax,"Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),[ng] / [ml],32.73,94807,DB00472,Fluoxetine
,9824228,AUC0-infinity,"Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),[ng] / [h·ml],1627,94808,DB00472,Fluoxetine
,9824228,Tmax,"Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),h,3.08,94809,DB00472,Fluoxetine
,9824228,ke,"Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),1/[h],0.022,94810,DB00472,Fluoxetine
,9824228,elimination half-life,"Analysis of fluoxetine concentrations in plasma samples from 18 volunteers following administration of a single 40 mg dose of fluoxetine provided the following pharmacokinetic data (mean+/-SD): Cmax, 32.73+/-9.21 ng/ml; AUC0-infinity, 1627+/-1372 ng/ml h; Tmax, 3.08 h (median); ke, 0.022+/-0.007 h(-1); elimination half-life, 37.69+/-21.70 h.","Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824228/),h,37.69,94811,DB00472,Fluoxetine
no less,28685967,extraction recovery,"The accuracy was in the range of 85-110%, and the extraction recovery was no less than 50%.",Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),%,50,94976,DB00472,Fluoxetine
,28685967,Cmax,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[mg] / [l],0.069,94977,DB00472,Fluoxetine
,28685967,AUC0→∞,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[h·mg] / [l],0.291,94978,DB00472,Fluoxetine
,28685967,Cmax,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[mg] / [l],0.046,94979,DB00472,Fluoxetine
,28685967,AUC0→∞,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[h·mg] / [l],0.181,94980,DB00472,Fluoxetine
,15866490,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (250 mmx4.6 mm, 5 microm, Germany) column, using water (formic acid 0.6 per thousand, ammonium acetate: 30 mmol/l)-acetonitrile (35:65, v/v) as mobile phase, with a flow-rate of 0.85 ml/min.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ml] / [min],0.85,96981,DB00472,Fluoxetine
above,15866490,extraction recoveries,The average extraction recoveries for all the four analytes were above 73.2%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,73.2,96982,DB00472,Fluoxetine
higher,15866490,recoveries,The methodology recoveries were higher than 95.0%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,95.0,96983,DB00472,Fluoxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.5,96984,DB00472,Fluoxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.3,96985,DB00472,Fluoxetine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.1,96986,DB00472,Fluoxetine
,11409190,Cmax,"Fluoxetine drops and marketed fluoxetine capsules had quite the same Cmax (50.25 +/- 4.43 vs 47.55 +/- 5.29 ng/ml), but significantly different AUC0-t (717.27 +/- 71.29 vs 644.91 +/- 78.91 ng/ml/h).",Comparative bioavailability of a new formulation of fluoxetine drops. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),[ng] / [ml],50.25,99366,DB00472,Fluoxetine
,11409190,Cmax,"Fluoxetine drops and marketed fluoxetine capsules had quite the same Cmax (50.25 +/- 4.43 vs 47.55 +/- 5.29 ng/ml), but significantly different AUC0-t (717.27 +/- 71.29 vs 644.91 +/- 78.91 ng/ml/h).",Comparative bioavailability of a new formulation of fluoxetine drops. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),[ng] / [ml],47.55,99367,DB00472,Fluoxetine
,11409190,AUC0-t,"Fluoxetine drops and marketed fluoxetine capsules had quite the same Cmax (50.25 +/- 4.43 vs 47.55 +/- 5.29 ng/ml), but significantly different AUC0-t (717.27 +/- 71.29 vs 644.91 +/- 78.91 ng/ml/h).",Comparative bioavailability of a new formulation of fluoxetine drops. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),[ng] / [h·ml],717.27,99368,DB00472,Fluoxetine
,11409190,AUC0-t,"Fluoxetine drops and marketed fluoxetine capsules had quite the same Cmax (50.25 +/- 4.43 vs 47.55 +/- 5.29 ng/ml), but significantly different AUC0-t (717.27 +/- 71.29 vs 644.91 +/- 78.91 ng/ml/h).",Comparative bioavailability of a new formulation of fluoxetine drops. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),[ng] / [h·ml],644.91,99369,DB00472,Fluoxetine
,11409190,Tmax,Furthermore the drops were characterised by a very early Tmax (4.61 +/- 0.85 hours) with a highly significant difference in comparison to the capsules reference compound (6.72 +/- 1.23 hours).,Comparative bioavailability of a new formulation of fluoxetine drops. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),h,4.61,99370,DB00472,Fluoxetine
,11409190,Tmax,Furthermore the drops were characterised by a very early Tmax (4.61 +/- 0.85 hours) with a highly significant difference in comparison to the capsules reference compound (6.72 +/- 1.23 hours).,Comparative bioavailability of a new formulation of fluoxetine drops. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11409190/),h,6.72,99371,DB00472,Fluoxetine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],3,99760,DB00472,Fluoxetine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],10,99761,DB00472,Fluoxetine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],2.0,99762,DB00472,Fluoxetine
,21594878,signal-to-noise ratios,"The limits of detection and quantitation at signal-to-noise ratios of 3 and 10 were 2.0 and 6.6 ng/mL, respectively.",Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594878/),[ng] / [ml],6.6,99763,DB00472,Fluoxetine
,24012861,steady-state plasma concentration (Css),"After transdermal administration of FX with IPM or the IPM-limonene mixture to rats, the mean steady-state plasma concentration (Css) was 66.20 or 77.55 ng/mL, respectively, which was maintained over 36 h and had a good correlation with the predicted Css from the in vitro data.",Effect of permeation enhancers on transdermal delivery of fluoxetine: in vitro and in vivo evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012861/),[ng] / [ml],66.20,101083,DB00472,Fluoxetine
,24012861,steady-state plasma concentration (Css),"After transdermal administration of FX with IPM or the IPM-limonene mixture to rats, the mean steady-state plasma concentration (Css) was 66.20 or 77.55 ng/mL, respectively, which was maintained over 36 h and had a good correlation with the predicted Css from the in vitro data.",Effect of permeation enhancers on transdermal delivery of fluoxetine: in vitro and in vivo evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24012861/),[ng] / [ml],77.55,101084,DB00472,Fluoxetine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00472,Fluoxetine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00472,Fluoxetine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00472,Fluoxetine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00472,Fluoxetine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00472,Fluoxetine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00472,Fluoxetine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00472,Fluoxetine
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.61,116091,DB00472,Fluoxetine
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.82,116092,DB00472,Fluoxetine
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],83.1,116345,DB00472,Fluoxetine
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],398.3,116346,DB00472,Fluoxetine
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],345.1,116347,DB00472,Fluoxetine
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],514.0,116348,DB00472,Fluoxetine
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],470.0,116349,DB00472,Fluoxetine
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],663.0,116350,DB00472,Fluoxetine
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],576.3,116351,DB00472,Fluoxetine
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],788.0,116352,DB00472,Fluoxetine
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],386.8,116353,DB00472,Fluoxetine
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],317.7,116354,DB00472,Fluoxetine
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],178.3,116355,DB00472,Fluoxetine
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],274.0,116356,DB00472,Fluoxetine
,31911203,total running time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,3,116719,DB00472,Fluoxetine
,31911203,retention time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,1.17,116720,DB00472,Fluoxetine
,31911203,retention time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,1.05,116721,DB00472,Fluoxetine
,11210405,Cmax,"Mean almotriptan Cmax was significantly higher following combination treatment with fluoxetine (52.5 +/- 11.9 ng/ml vs. 44.3 +/- 10.9 ng/ml, p = 0.023).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[ng] / [ml],52.5,117528,DB00472,Fluoxetine
,11210405,Cmax,"Mean almotriptan Cmax was significantly higher following combination treatment with fluoxetine (52.5 +/- 11.9 ng/ml vs. 44.3 +/- 10.9 ng/ml, p = 0.023).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[ng] / [ml],44.3,117529,DB00472,Fluoxetine
,11210405,AUC0-infinity,"Mean AUC0-infinity was not significantly affected by fluoxetine coadministration (353 +/- 55.7 ng.h/ml vs. 333 +/- 33.6 ng.h/ml, p = 0.059).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[h·ng] / [ml],353,117530,DB00472,Fluoxetine
,11210405,AUC0-infinity,"Mean AUC0-infinity was not significantly affected by fluoxetine coadministration (353 +/- 55.7 ng.h/ml vs. 333 +/- 33.6 ng.h/ml, p = 0.059).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[h·ng] / [ml],333,117531,DB00472,Fluoxetine
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,5.0,119549,DB00472,Fluoxetine
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,4.0,119550,DB00472,Fluoxetine
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,20,119551,DB00472,Fluoxetine
,11270912,t1/2,"In the elderly volunteers, the t1/2 for fluoxetine was 25% longer (5.0 vs. 4.0 days) and for norfluoxetine was 33% longer (20 vs. 15 days), although variability and sample size precluded statistical significance.",Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270912/),d,15,119552,DB00472,Fluoxetine
,12353056,absolute bioavailability,Almotriptan is well absorbed orally; its absolute bioavailability in humans is 70%.,"Almotriptan, a new anti-migraine agent: a review. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),%,70,123996,DB00472,Fluoxetine
,12353056,elimination half-life,Its peak plasma levels are reached at 1 to 3 h after its administration; its elimination half-life is 3 to 4 h.,"Almotriptan, a new anti-migraine agent: a review. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),h,3 to 4,123997,DB00472,Fluoxetine
,10989270,steady-state brain concentrations,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),μM,12,124549,DB00472,Fluoxetine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,10,124550,DB00472,Fluoxetine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),μM,13,124551,DB00472,Fluoxetine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,10,124552,DB00472,Fluoxetine
,10989270,brain elimination half-life,Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),h,79,124553,DB00472,Fluoxetine
,10989270,brain elimination half-life,Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),h,382,124554,DB00472,Fluoxetine
,10989270,brain-to-plasma-half-life-ratio,"Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 +/- 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 +/- 0.3; n = 2).",Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,2.2,124555,DB00472,Fluoxetine
,10989270,brain-to-plasma-half-life-ratio,"Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 +/- 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 +/- 0.3; n = 2).",Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,1.0,124556,DB00472,Fluoxetine
,15848211,Recoveries,"Recoveries ranged from 89.7 to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively.",Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848211/),%,89.7 to 96.6,124818,DB00472,Fluoxetine
,15848211,Recoveries,"Recoveries ranged from 89.7 to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively.",Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848211/),%,80.2 to 85.3,124819,DB00472,Fluoxetine
,9068931,half-life (t1/2),Most SSRIs have a half-life (t1/2) of approximately 1 day.,Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,1,129521,DB00472,Fluoxetine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,2 to 4,129522,DB00472,Fluoxetine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,7 to 15,129523,DB00472,Fluoxetine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00472,Fluoxetine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00472,Fluoxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,81 to 118,129741,DB00472,Fluoxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,73 to 95,129742,DB00472,Fluoxetine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,39 to 66,129743,DB00472,Fluoxetine
,8470355,concentrations,"Red cell and plasma fluoxetine concentrations were 493 +/- 79 ng/ml and 454 +/- 53 ng/ml, respectively (P > 0.1).",Red cell and plasma concentrations of fluoxetine and norfluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8470355/),[ng] / [ml],454,130530,DB00472,Fluoxetine
,25650979,steady-state clearance,The mean maternal baboon steady-state clearance of fluoxetine (42 mL/min/kg) was considerably higher than that in humans.,Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650979/),[ml] / [kg·min],42,136664,DB00472,Fluoxetine
,25650979,metabolite-to-drug ratio,"Norfluoxetine, the major active metabolite, had a higher metabolite-to-drug ratio (8.7) than that found in humans, particularly with oral dosing.",Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650979/),,8.7,136665,DB00472,Fluoxetine
,25650979,clearance,The fetal clearance of fluoxetine (303 ± 176 mL/min) and norfluoxetine (450 mL/min) exceeded reported placental blood flow.,Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650979/),[ml] / [min],303,136666,DB00472,Fluoxetine
,25650979,clearance,The fetal clearance of fluoxetine (303 ± 176 mL/min) and norfluoxetine (450 mL/min) exceeded reported placental blood flow.,Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650979/),[ml] / [min],450,136667,DB00472,Fluoxetine
,12926591,Relative bioavailability,Relative bioavailability of each dose administered via the TD route was 10% of the value for oral administration of the drug.,Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926591/),%,10,145652,DB00472,Fluoxetine
,12926591,plasma elimination half-life,"Mean plasma elimination half-life after oral administration was 47 and 55 hours for fluoxetine and norfluoxetine, respectively.",Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926591/),h,47,145653,DB00472,Fluoxetine
,12926591,plasma elimination half-life,"Mean plasma elimination half-life after oral administration was 47 and 55 hours for fluoxetine and norfluoxetine, respectively.",Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926591/),h,55,145654,DB00472,Fluoxetine
,12926591,relative bioavailability,"However, the relative bioavailability for TD administration is approximately only 10% of that for the oral route of administration.",Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926591/),%,10,145655,DB00472,Fluoxetine
,8844419,Recoveries,Recoveries ranged from 50 to 66% for the three compounds.,Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8844419/),%,50 to 66,145913,DB00472,Fluoxetine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],2.7,146251,DB00472,Fluoxetine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],3.0,146252,DB00472,Fluoxetine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.33,146253,DB00472,Fluoxetine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.188,146254,DB00472,Fluoxetine
,30346625,apparent clearance,"The apparent clearance of (S)-(+)-FLX (1.45 vs. 0.66 L/hour/kg) and the area under the plasma concentration vs. time curve (AUC) of the (S)-(+)-NorFLX (AUC0-∞ 942.7 vs. 498.6 ng hour/mL) were higher (P < 0.05) than those of the respective (R)-(-) enantiomers, indicating that the (S)-(+)-FLX enantiomer is preferentially metabolized to (S)-(+)-NorFLX.",Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30346625/),[l] / [h·kg],1.45,147023,DB00472,Fluoxetine
,30346625,apparent clearance,"The apparent clearance of (S)-(+)-FLX (1.45 vs. 0.66 L/hour/kg) and the area under the plasma concentration vs. time curve (AUC) of the (S)-(+)-NorFLX (AUC0-∞ 942.7 vs. 498.6 ng hour/mL) were higher (P < 0.05) than those of the respective (R)-(-) enantiomers, indicating that the (S)-(+)-FLX enantiomer is preferentially metabolized to (S)-(+)-NorFLX.",Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30346625/),[l] / [h·kg],0.66,147024,DB00472,Fluoxetine
,30346625,AUC0-∞,"The apparent clearance of (S)-(+)-FLX (1.45 vs. 0.66 L/hour/kg) and the area under the plasma concentration vs. time curve (AUC) of the (S)-(+)-NorFLX (AUC0-∞ 942.7 vs. 498.6 ng hour/mL) were higher (P < 0.05) than those of the respective (R)-(-) enantiomers, indicating that the (S)-(+)-FLX enantiomer is preferentially metabolized to (S)-(+)-NorFLX.",Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30346625/),[h·ng] / [ml],942.7,147025,DB00472,Fluoxetine
,30346625,AUC0-∞,"The apparent clearance of (S)-(+)-FLX (1.45 vs. 0.66 L/hour/kg) and the area under the plasma concentration vs. time curve (AUC) of the (S)-(+)-NorFLX (AUC0-∞ 942.7 vs. 498.6 ng hour/mL) were higher (P < 0.05) than those of the respective (R)-(-) enantiomers, indicating that the (S)-(+)-FLX enantiomer is preferentially metabolized to (S)-(+)-NorFLX.",Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30346625/),[h·ng] / [ml],498.6,147026,DB00472,Fluoxetine
,30346625,place,"The placental transfer (umbilical vein/maternal vein) of FLX and NorFLX is low (30-40%), with the predominant transfer of (S)-(+)-FLX (44 vs. 33%).",Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30346625/),%,30,147027,DB00472,Fluoxetine
,20063149,total run time,Derivatives were then separated on a gas chromatograph coupled with a triple-quadrupole mass spectrometer operating in negative selected reaction monitoring mode for a total run time of 5 min.,"Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),min,5,147690,DB00472,Fluoxetine
,20063149,limit of detection,"Despite the small sampling volume, the limit of detection was estimated at 20 pg mL(-1) for all the analytes.","Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),[pg] / [ml],20,147691,DB00472,Fluoxetine
,1531816,elimination half-life,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,2 to 3,152373,DB00472,Fluoxetine
,1531816,half-lives,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,1,152374,DB00472,Fluoxetine
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],522,153234,DB00472,Fluoxetine
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],927,153235,DB00472,Fluoxetine
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],244,153236,DB00472,Fluoxetine
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],330,153237,DB00472,Fluoxetine
,11225566,apparent oral clearance,Mean apparent oral clearance for both enantiomers decreased significantly with fluoxetine administration (R(+): 10.3 +/- 7.2 vs.,"Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),,10.3,153238,DB00472,Fluoxetine
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],22.5,153239,DB00472,Fluoxetine
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],12.6,153240,DB00472,Fluoxetine
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB00472,Fluoxetine
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB00472,Fluoxetine
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB00472,Fluoxetine
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB00472,Fluoxetine
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB00472,Fluoxetine
,23362155,AUC,"In animals exposed to gasoline, we observed an increase in AUC(0-∞) for both enantiomers, with a sharper increase seen for the (-)-(R)-fluoxetine enantiomer (enantiomeric ratio AUC((+)-(S)/(-)-(R)) = 1.07), resulting in a loss of enantioselectivity.",Influence of gasoline inhalation on the enantioselective pharmacokinetics of fluoxetine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362155/),,1.07,158762,DB00472,Fluoxetine
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00472,Fluoxetine
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00472,Fluoxetine
less,1564047,plasma ratio,"However, the plasma ratio of fluoxetine to norfluoxetine was less than 1.0 in all patients reporting sedation and greater than 1.0 in all patients without sedation.",Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564047/),,1.0,160252,DB00472,Fluoxetine
greater,1564047,plasma ratio,"However, the plasma ratio of fluoxetine to norfluoxetine was less than 1.0 in all patients reporting sedation and greater than 1.0 in all patients without sedation.",Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564047/),,1.0,160253,DB00472,Fluoxetine
,22032156,flow rate,"The gradient elution of acetonitrile and water (containing 0.05% (v/v) formic acid) as mobile phases was performed at a flow rate of 200 microL/min, and a rapid separation was completed in 5 min.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),[μl] / [min],200,160740,DB00472,Fluoxetine
,22032156,limit of detection,The calibration curve showed good linearity within the concentrations of 1 to 1 000 microg/L (r = 0.999 1); the limit of detection was 0.2 microg/L.,[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),[μg] / [l],0.2,160741,DB00472,Fluoxetine
,22032156,recoveries,"The mean recoveries were from 85% to 115% at the spiked levels of 5, 50 and 500 microg/L; the relative standard deviations (RSDs) of intra- and inter-day of variation were both less than 15%, which can meet the determination requirements of biological samples.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),%,85,160742,DB00472,Fluoxetine
,22032156,recoveries,"The mean recoveries were from 85% to 115% at the spiked levels of 5, 50 and 500 microg/L; the relative standard deviations (RSDs) of intra- and inter-day of variation were both less than 15%, which can meet the determination requirements of biological samples.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),%,115,160743,DB00472,Fluoxetine
,9272409,metabolic ratio (MR),"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),,9.2,162238,DB00472,Fluoxetine
,9272409,MRp,"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),,2.4,162239,DB00472,Fluoxetine
,9272409,clearance,"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],4190,162240,DB00472,Fluoxetine
,9272409,half-life,"The patient's caffeine half-life was 10 h, thus, precluding ultra-rapid metabolism for CYP1A2.",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),h,10,162241,DB00472,Fluoxetine
,9272409,MRP,"Subsequently, MRP of maprotiline (4.9) and CLM were reduced (1900 ml.min-1; expected CLM in poor metabolisers: of CYP2D6 364).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],4.9,162242,DB00472,Fluoxetine
,9272409,MRP,"Subsequently, MRP of maprotiline (4.9) and CLM were reduced (1900 ml.min-1; expected CLM in poor metabolisers: of CYP2D6 364).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],1900,162243,DB00472,Fluoxetine
,30981192,limit of detection (LOD),"Furthermore, the method was validated according to the International Conference on Harmonization (ICH) guidelines and could be used to detect DCV in plasma over a linear range of 1.0-4000 ng/mL, with an acceptable sensitivity as the limit of detection (LOD) was 0.025 ng/mL.",A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981192/),[ng] / [ml],0.025,164137,DB00472,Fluoxetine
,18980116,flow rate,"Separations were performed in the isocratic mode on a Nucleosil CN column with the mobile phase acetonitrile-10 mM sodium acetate buffer (pH 3.5)-methanol (47 + 47 + 6, v/v/v) at a flow rate of 1.0 mL/min.","Nonextractive procedure and precolumn derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole for trace determination of trimetazidine in plasma by high-performance liquid chromatography with fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980116/),[ml] / [min],1.0,164601,DB00472,Fluoxetine
,18980116,recoveries,The accuracy of the method was demonstrated; the recoveries of TMZ from spiked human plasma were 98.13-102.83 +/- 0.2-4.04%.,"Nonextractive procedure and precolumn derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole for trace determination of trimetazidine in plasma by high-performance liquid chromatography with fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980116/),%,98.13-102.83,164602,DB00472,Fluoxetine
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,41.8,166072,DB00472,Fluoxetine
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,68.7,166073,DB00472,Fluoxetine
>,19272843,m/z,The transition monitored were m/z 285>44 for mazindol and m/z 310>44 for IS.,Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),,285,167524,DB00472,Fluoxetine
>,19272843,m/z,The transition monitored were m/z 285>44 for mazindol and m/z 310>44 for IS.,Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),,44,167525,DB00472,Fluoxetine
>,19272843,m/z 310,The transition monitored were m/z 285>44 for mazindol and m/z 310>44 for IS.,Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),,44,167526,DB00472,Fluoxetine
,19272843,flow-rate,"Chromatographic separation was achieved on a Capcell Pak MGII C(18) column using an isocratic mobile phase, consisting of acetonitrile-20mM ammonium formate in water (50:50, v/v, adjusted to pH 3.5 with formic acid) at a flow-rate of 0.2mL/min.",Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),[ml] / [min],0.2,167527,DB00472,Fluoxetine
,19272843,retention times,"The retention times of mazindol and fluoxetine were 1.03min and 1.45min, respectively.",Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),min,1.03,167528,DB00472,Fluoxetine
,19272843,retention times,"The retention times of mazindol and fluoxetine were 1.03min and 1.45min, respectively.",Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272843/),min,1.45,167529,DB00472,Fluoxetine
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB00472,Fluoxetine
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],80.6,168463,DB00472,Fluoxetine
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],52.6,168464,DB00472,Fluoxetine
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],85.3,168465,DB00472,Fluoxetine
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],90,168466,DB00472,Fluoxetine
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],42.4,168467,DB00472,Fluoxetine
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],14.9,168468,DB00472,Fluoxetine
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,0.75,168469,DB00472,Fluoxetine
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,1.27,168470,DB00472,Fluoxetine
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.028,169584,DB00472,Fluoxetine
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.080,169585,DB00472,Fluoxetine
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],75.01,169586,DB00472,Fluoxetine
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],49.36,169587,DB00472,Fluoxetine
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],107.62,169588,DB00472,Fluoxetine
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],70.60,169589,DB00472,Fluoxetine
,11043675,flow rate,"Liquid chromatographic parameters for CD were as follows: a mobile phase composition of methanol/0.3% triethylamine buffer, pH 5.6, (30:70), a flow rate of 1 mL/min, detection at 214 nm, and a temperature of 40 degrees C.","Chiral high-performance liquid chromatographic analysis of fluoxetine and norfluoxetine in rabbit plasma, urine, and vitreous humor using an acetylated beta-cyclodextrin column. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043675/),[ml] / [min],1,174398,DB00472,Fluoxetine
,12454556,steady-state FLX,"Mean steady-state FLX and NORFLX of 127 ng/mL and 151 ng/mL, respectively, were achieved in children and adolescents after 4 weeks of treatment, with high between-patient variability.",Fluoxetine pharmacokinetics in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454556/),[ng] / [ml],127,177418,DB00472,Fluoxetine
,12454556,NORFLX,"Mean steady-state FLX and NORFLX of 127 ng/mL and 151 ng/mL, respectively, were achieved in children and adolescents after 4 weeks of treatment, with high between-patient variability.",Fluoxetine pharmacokinetics in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454556/),[ng] / [ml],151,177419,DB00472,Fluoxetine
,3262026,t1/2,The mean t1/2 was 6.6 vs.,Fluoxetine disposition and elimination in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262026/),,6.6,184113,DB00472,Fluoxetine
,3262026,plasma clearance,2.2 days and plasma clearance was 4.2 vs.,Fluoxetine disposition and elimination in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262026/),,4.2,184114,DB00472,Fluoxetine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],37.8 to 173,192832,DB00472,Fluoxetine
,9241008,maximum concentration in plasma (Cmax),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],36.1 to 51.9,192833,DB00472,Fluoxetine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],"634 to 3,305",192834,DB00472,Fluoxetine
,9241008,area under the concentration-time curve (AUC[24]),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[h·ng] / [ml],611 to 838,192835,DB00472,Fluoxetine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.5 to 113,192836,DB00472,Fluoxetine
,9241008,trough value (C0),"After 10 days of coadministration at the lower dose, mean desipramine maximum concentration in plasma (Cmax) relative to baseline increased from 37.8 to 173 ng/mL (+358%) with paroxetine versus from 36.1 to 51.9 ng/mL (+44%) with sertraline; the mean desipramine 24-hour area under the concentration-time curve (AUC[24]) increased from 634 to 3,305 ng x h/mL (+421%) with paroxetine versus from 611 to 838 ng x h/mL (+37%) with sertraline; and the mean desipramine trough value (C0) increased from 18.5 to 113 ng/mL (+511%) with paroxetine versus from 18.3 to 21.8 ng/mL (+19%) with sertraline (all increases, p < 0.001).",Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241008/),[ng] / [ml],18.3 to 21.8,192837,DB00472,Fluoxetine
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB00472,Fluoxetine
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB00472,Fluoxetine
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB00472,Fluoxetine
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB00472,Fluoxetine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB00472,Fluoxetine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB00472,Fluoxetine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,23,199315,DB00472,Fluoxetine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,60,199316,DB00472,Fluoxetine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,34,199317,DB00472,Fluoxetine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,41,199318,DB00472,Fluoxetine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,64,199319,DB00472,Fluoxetine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,47,199320,DB00472,Fluoxetine
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,17,199321,DB00472,Fluoxetine
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,167,199322,DB00472,Fluoxetine
,22923967,mass-to-charge ratio (m/z),"The ions chosen were of a mass-to-charge ratio (m/z) exactly equal to 44 units, in order to measure fluoxetine enantiomers, 134 units in order to measure norfluoxetine enantiomers, and 58 units in order to measure diphenhydramine, the internal standard.",A novel chiral GC/MS method for the analysis of fluoxetine and norfluoxetine enantiomers in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923967/),units,44,199689,DB00472,Fluoxetine
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00472,Fluoxetine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00472,Fluoxetine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00472,Fluoxetine
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00472,Fluoxetine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00472,Fluoxetine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00472,Fluoxetine
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00472,Fluoxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00472,Fluoxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00472,Fluoxetine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00472,Fluoxetine
,9660843,t1/2,"There was a statistically significantly increased t1/2 for zolpidem on night 32, compared with night 28 (3.64 and 3.29 hr, respectively).",Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660843/),h,3.64,202340,DB00472,Fluoxetine
,9660843,t1/2,"There was a statistically significantly increased t1/2 for zolpidem on night 32, compared with night 28 (3.64 and 3.29 hr, respectively).",Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660843/),h,3.29,202341,DB00472,Fluoxetine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,0.2,202649,DB00472,Fluoxetine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,2.2,202650,DB00472,Fluoxetine
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00472,Fluoxetine
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00472,Fluoxetine
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00472,Fluoxetine
,28648684,tmax,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),min,5,206121,DB00472,Fluoxetine
,28648684,half-life (t0.5,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),min,74,206122,DB00472,Fluoxetine
,28648684,volume of distribution (Vss,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),[l] / [kg],3.7,206123,DB00472,Fluoxetine
,28648684,bioavailability,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),%,25,206124,DB00472,Fluoxetine
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB00472,Fluoxetine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB00472,Fluoxetine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB00472,Fluoxetine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB00472,Fluoxetine
,30008307,extraction recoveries,"The extraction recoveries were 75%-85% for olanzapine and olanzapine‑d3, and 58%-69% for fluoxetine, norfluoxetine, and their deuterated internal standards.","Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30008307/),%,75,211305,DB00472,Fluoxetine
,30008307,extraction recoveries,"The extraction recoveries were 75%-85% for olanzapine and olanzapine‑d3, and 58%-69% for fluoxetine, norfluoxetine, and their deuterated internal standards.","Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30008307/),%,58,211306,DB00472,Fluoxetine
lower,28550529,brain/plasma ratio,HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration permeated the blood-brain barrier with brain/plasma ratio lower than 1.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),,1,216164,DB00472,Fluoxetine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,15,216165,DB00472,Fluoxetine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,54,216166,DB00472,Fluoxetine
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3739,216252,DB00472,Fluoxetine
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3498,216253,DB00472,Fluoxetine
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.58,216254,DB00472,Fluoxetine
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.92,216255,DB00472,Fluoxetine
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,39.5,216256,DB00472,Fluoxetine
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,38.2,216257,DB00472,Fluoxetine
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.32,216258,DB00472,Fluoxetine
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.05,216259,DB00472,Fluoxetine
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216260,DB00472,Fluoxetine
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216261,DB00472,Fluoxetine
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216262,DB00472,Fluoxetine
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216263,DB00472,Fluoxetine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],289,219612,DB00472,Fluoxetine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],112,219613,DB00472,Fluoxetine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],27,219614,DB00472,Fluoxetine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],181,219615,DB00472,Fluoxetine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],87,219616,DB00472,Fluoxetine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],51,219617,DB00472,Fluoxetine
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,1 to 4,219943,DB00472,Fluoxetine
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,7 to 15,219944,DB00472,Fluoxetine
up to,9613947,recoveries,The method provides recoveries of up to 90% for both compounds.,Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613947/),%,90,222053,DB00472,Fluoxetine
,9613947,limit of detection,The limit of detection was 5.0 ng/ml.,Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613947/),[ng] / [ml],5.0,222054,DB00472,Fluoxetine
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB00472,Fluoxetine
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB00472,Fluoxetine
,17696212,LOD,"The LOD in plasma were 4 ng/mL (S/N = 3), a value comparable to that obtained using LC-MS, showing the success of the on-line stacking technique.",On-line sample stacking and short-end injection CE for the determination of fluoxetine and norfluoxetine in plasma: Method development and validation using experimental designs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17696212/),[ng] / [ml],4,226727,DB00472,Fluoxetine
,17696212,S/N,"The LOD in plasma were 4 ng/mL (S/N = 3), a value comparable to that obtained using LC-MS, showing the success of the on-line stacking technique.",On-line sample stacking and short-end injection CE for the determination of fluoxetine and norfluoxetine in plasma: Method development and validation using experimental designs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17696212/),,3,226728,DB00472,Fluoxetine
,34341510,IC50,"Among 6 known K2P channel modulators tested (DCPIB, quinine, fluoxetine, ML365, ML335, and TKDC), ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07 ± 1.5 μM.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),μM,4.07,233069,DB00472,Fluoxetine
,34341510,F,"In a preliminary pharmacokinetic study conducted in rats, ML365 showed good absolute oral bioavailability with F value of 22.49%.",ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341510/),%,22.49,233070,DB00472,Fluoxetine
,11199945,times to sustained response,The median times to sustained response (> or = 50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01).,"Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,19,237298,DB00472,Fluoxetine
,11199945,times to sustained response,The median times to sustained response (> or = 50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01).,"Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,29,237299,DB00472,Fluoxetine
,11199945,Ki,"Mean values were approximately 26 nM, a concentration higher than the Ki of (-)pindolol for human 5-HT1A autoreceptors (11 nM).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),nM,11,237300,DB00472,Fluoxetine
,11199945,time to sustained response,"A comparison of the data of all sustained responders (N = 27) in the fluoxetine-plus-placebo group with the first 27 responders in the fluoxetine-plus-pindolol group (of a total of 38) revealed a highly significant difference in the time to sustained response (18 and 10 days, respectively; p = 0.0002).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,18,237301,DB00472,Fluoxetine
,11199945,time to sustained response,"A comparison of the data of all sustained responders (N = 27) in the fluoxetine-plus-placebo group with the first 27 responders in the fluoxetine-plus-pindolol group (of a total of 38) revealed a highly significant difference in the time to sustained response (18 and 10 days, respectively; p = 0.0002).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,10,237302,DB00472,Fluoxetine
,8213289,"minimum plasmatic concentration""","By means of serial Chi-score calculation we found a ""minimum plasmatic concentration"" of about 30 ng/ml below which there was less therapeutic response.","[Plasmatic concentrations of fluoxetine, pharmacokinetics, therapeutic response and side effects]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213289/),[ng] / [ml],30,237809,DB00472,Fluoxetine
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,47.30,238596,DB00472,Fluoxetine
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,33.23,238597,DB00472,Fluoxetine
,8632299,Vmax,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[nM] / [mg·min],10.3,240628,DB00472,Fluoxetine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,304,240629,DB00472,Fluoxetine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,2.4,240630,DB00472,Fluoxetine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,74,240631,DB00472,Fluoxetine
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.006,240632,DB00472,Fluoxetine
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.023,240633,DB00472,Fluoxetine
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.6,240634,DB00472,Fluoxetine
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,1.7,240635,DB00472,Fluoxetine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,2.7,240636,DB00472,Fluoxetine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,8.0,240637,DB00472,Fluoxetine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,7.0,240638,DB00472,Fluoxetine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,44.3,240639,DB00472,Fluoxetine
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],41,240640,DB00472,Fluoxetine
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],337,240641,DB00472,Fluoxetine
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,13.5,240642,DB00472,Fluoxetine
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,3.4,240643,DB00472,Fluoxetine
,3871765,half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,1-3,240991,DB00472,Fluoxetine
,3871765,plasma half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,7-15,240992,DB00472,Fluoxetine
,11453896,"AUC(0, 192 h)","Mean +/- (s.d) norfluoxetine AUC(0, 192 h) was significantly lower in PMs than that in EMs (1343 +/- 277 vs 2935 +/- 311, P < 0.001).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,1343,243081,DB00472,Fluoxetine
,11453896,"AUC(0, 192 h)","Mean +/- (s.d) norfluoxetine AUC(0, 192 h) was significantly lower in PMs than that in EMs (1343 +/- 277 vs 2935 +/- 311, P < 0.001).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,2935,243082,DB00472,Fluoxetine
,11453896,Cmax,"Mean fluoxetine Cmax and AUC(0, infinity) in wild-type homozygotes (CYP2C19*1/CYP2C19*1) were significantly lower than that in PMs (22.4 +/- 3.9 vs 36.7 +/- 8.9, P < 0.001; 732 +/- 42 vs 2152 +/- 492, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,22.4,243083,DB00472,Fluoxetine
,11453896,"AUC(0, infinity)","Mean fluoxetine Cmax and AUC(0, infinity) in wild-type homozygotes (CYP2C19*1/CYP2C19*1) were significantly lower than that in PMs (22.4 +/- 3.9 vs 36.7 +/- 8.9, P < 0.001; 732 +/- 42 vs 2152 +/- 492, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,732,243084,DB00472,Fluoxetine
,11453896,"AUC(0, infinity)","Mean fluoxetine Cmax and AUC(0, infinity) in wild-type homozygotes (CYP2C19*1/CYP2C19*1) were significantly lower than that in PMs (22.4 +/- 3.9 vs 36.7 +/- 8.9, P < 0.001; 732 +/- 42 vs 2152 +/- 492, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,2152,243085,DB00472,Fluoxetine
,11453896,oral clearance,"Mean oral clearance in individuals with the wild type homozygous genotype was significantly higher than that in heterozygotes and that in PMs (54.7 +/- 3.4 vs 36.0 +/- 8.7, P < 0.01; 54.7 +/- 3.4 vs 20.6 +/- 6.2, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,54.7,243086,DB00472,Fluoxetine
,11453896,oral clearance,"Mean oral clearance in individuals with the wild type homozygous genotype was significantly higher than that in heterozygotes and that in PMs (54.7 +/- 3.4 vs 36.0 +/- 8.7, P < 0.01; 54.7 +/- 3.4 vs 20.6 +/- 6.2, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,36.0,243087,DB00472,Fluoxetine
,11453896,oral clearance,"Mean oral clearance in individuals with the wild type homozygous genotype was significantly higher than that in heterozygotes and that in PMs (54.7 +/- 3.4 vs 36.0 +/- 8.7, P < 0.01; 54.7 +/- 3.4 vs 20.6 +/- 6.2, P < 0.001, respectively).",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,20.6,243088,DB00472,Fluoxetine
,11453896,"AUC(0, 192 h)","Mean norfluoxetine AUC(0, 192 h) in PMs was significantly lower than that in wild type homozygotes (1343 +/- 277 vs 3163 +/- 121, P < 0.05) and that in heterozygotes (1343 +/- 277 vs 2706 +/- 273, P < 0.001), respectively.",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,1343,243089,DB00472,Fluoxetine
,11453896,"AUC(0, 192 h)","Mean norfluoxetine AUC(0, 192 h) in PMs was significantly lower than that in wild type homozygotes (1343 +/- 277 vs 3163 +/- 121, P < 0.05) and that in heterozygotes (1343 +/- 277 vs 2706 +/- 273, P < 0.001), respectively.",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,3163,243090,DB00472,Fluoxetine
,11453896,"AUC(0, 192 h)","Mean norfluoxetine AUC(0, 192 h) in PMs was significantly lower than that in wild type homozygotes (1343 +/- 277 vs 3163 +/- 121, P < 0.05) and that in heterozygotes (1343 +/- 277 vs 2706 +/- 273, P < 0.001), respectively.",Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11453896/),,2706,243091,DB00472,Fluoxetine
,10516940,Cmax,"The mean pharmacokinetic parameters for extensive fluoxetine metabolizers were 27.0 ng ml-1 for Cmax, 2064.0 ng h ml-1 for AUC(0-infinity), and 85.4 h t1/2.",Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516940/),[ng] / [ml],27.0,244902,DB00472,Fluoxetine
,10516940,AUC(0-infinity),"The mean pharmacokinetic parameters for extensive fluoxetine metabolizers were 27.0 ng ml-1 for Cmax, 2064.0 ng h ml-1 for AUC(0-infinity), and 85.4 h t1/2.",Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516940/),[h·ng] / [ml],2064.0,244903,DB00472,Fluoxetine
,10516940,t1/2,"The mean pharmacokinetic parameters for extensive fluoxetine metabolizers were 27.0 ng ml-1 for Cmax, 2064.0 ng h ml-1 for AUC(0-infinity), and 85.4 h t1/2.",Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516940/),h,85.4,244904,DB00472,Fluoxetine
,10516940,AUC(0-infinity),The mean pharmacokinetic parameters for norfluoxetine (in extensive metabolizers only) were 2532.0 ng h ml-1 for AUC(0-infinity) and 8.4 ng ml-1 for Cmax.,Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516940/),[h·ng] / [ml],2532.0,244905,DB00472,Fluoxetine
,10516940,Cmax,The mean pharmacokinetic parameters for norfluoxetine (in extensive metabolizers only) were 2532.0 ng h ml-1 for AUC(0-infinity) and 8.4 ng ml-1 for Cmax.,Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516940/),[ng] / [ml],8.4,244906,DB00472,Fluoxetine
,14744943,area under the plasma concentration versus time curve (AUC) ratios,"They rapidly crossed the placenta [maternal to fetal area under the plasma concentration versus time curve (AUC) ratios 0.59 and 0.65, respectively].",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,0.59,245946,DB00472,Fluoxetine
,14744943,area under the plasma concentration versus time curve (AUC) ratios,"They rapidly crossed the placenta [maternal to fetal area under the plasma concentration versus time curve (AUC) ratios 0.59 and 0.65, respectively].",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,0.65,245947,DB00472,Fluoxetine
,14744943,AUC ratios,"There was significant FX stereoselectivity with S/R FX AUC ratios averaging 1.65 +/- 0.33 and 1.73 +/- 0.29 in ewe and fetus, respectively, after maternal dosing.",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,1.65,245948,DB00472,Fluoxetine
,14744943,AUC ratios,"There was significant FX stereoselectivity with S/R FX AUC ratios averaging 1.65 +/- 0.33 and 1.73 +/- 0.29 in ewe and fetus, respectively, after maternal dosing.",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,1.73,245949,DB00472,Fluoxetine
,14744943,free fraction S/R FX ratio,"Both FX and NFX were extensively and stereoselectively bound in maternal and fetal plasma, with the free fraction S/R FX ratio averaging 0.46 +/- 0.06 and 0.58 +/- 0.10 in ewe and fetus, respectively.",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,0.46,245950,DB00472,Fluoxetine
,14744943,free fraction S/R FX ratio,"Both FX and NFX were extensively and stereoselectively bound in maternal and fetal plasma, with the free fraction S/R FX ratio averaging 0.46 +/- 0.06 and 0.58 +/- 0.10 in ewe and fetus, respectively.",Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744943/),,0.58,245951,DB00472,Fluoxetine
,12709723,trough,"The fluoxetine dose from 20 mg to 40 mg once daily resulted in relatively low trough fluoxetine-norfluoxetine concentrations during pregnancy (range, 317-850 nmol/L).",Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709723/),[nM] / [l],317-850,248587,DB00472,Fluoxetine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],105.93,248946,DB00472,Fluoxetine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],134.97,248947,DB00472,Fluoxetine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],11.6,248948,DB00472,Fluoxetine
,1855347,area under the concentration-time curve,Addition of fluoxetine resulted in a significant increase in the area under the concentration-time curve of carbamazepine (105.93 +/- 18.05 micrograms/ml.hr versus 134.97 +/- 12.15 micrograms/ml.hr; t = 3.284; df = 5; p = 0.022) and CBZE (11.6 +/- 1.93 micrograms/ml.hr versus 15.2 +/- 2.4 micrograms/ml.hr; t = 2.805; df = 5; p = 0.038).,Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[μg] / [h·ml],15.2,248949,DB00472,Fluoxetine
,1855347,oral,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],3.87,248950,DB00472,Fluoxetine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],2.98,248951,DB00472,Fluoxetine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],17.90,248952,DB00472,Fluoxetine
,1855347,intrinsic clearance,"Both oral and intrinsic clearance of carbamazepine was decreased significantly on fluoxetine addition (3.87 +/- 0.68 L/hr versus 2.98 +/- 0.26 L/hr; t = 3.025; df = 5; p = 0.029 and 17.90 +/- 4.9 L/hr versus 11.92 +/- 1.4 L/hr; t = 3.037; df = 5; p = 0.029, respectively).",Increased carbamazepine plasma concentrations after fluoxetine coadministration. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855347/),[l] / [h],11.92,248953,DB00472,Fluoxetine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,2.4,251481,DB00472,Fluoxetine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,4.9,251482,DB00472,Fluoxetine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),,1.8,251483,DB00472,Fluoxetine
,11026739,relative oral bioavailability,"In healthy volunteers, the relative oral bioavailability, calculated as the ratio AUC 0-infinity fluoxetine HCl/gamma-cyclodextrin on AUC 0-infinity fluoxetine HCl (20 mg PO), was equal to 249.9%.","The inclusion of fluoxetine into gamma-cyclodextrin increases its bioavailability: behavioral, electrophysiological and pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11026739/),%,249.9,251535,DB00472,Fluoxetine
,1478986,limit of detection,The limit of detection is 2.0 ng/ml for both FLU and N-FLU.,Sensitive micromethod for column liquid chromatographic determination of fluoxetine and norfluoxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1478986/),[ng] / [ml],2.0,251815,DB00472,Fluoxetine
,15643102,relative bioavailability,"The relative bioavailability of rectally administered fluoxetine was approximately 15% [norfluoxetine, 95% CI 9-21%, and total (fluoxetine + norfluoxetine), 95% CI 8-22%].",Relative rectal bioavailability of fluoxetine in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15643102/),%,15,251884,DB00472,Fluoxetine
,15643102,relative bioavailability,"The relative bioavailability of rectally administered fluoxetine was approximately 15% [norfluoxetine, 95% CI 9-21%, and total (fluoxetine + norfluoxetine), 95% CI 8-22%].",Relative rectal bioavailability of fluoxetine in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15643102/),,total,251885,DB00472,Fluoxetine
,1949975,plasma elimination half-life,"Sertraline follows first-order kinetics, with a plasma elimination half-life of 24-26 hours.",Sertraline: a new specific serotonin reuptake blocker. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949975/),h,24-26,254299,DB00472,Fluoxetine
,17176627,Cmax,"The mean pharmacokinetic parameters for both of the drugs under study were as follows: Cmax = 61.24 (+/- 12.96) ng/ml for the test formulation, and for the reference formulation Cmax = 61.39 (+/- 14.1) ng/ml, the effects were statistically equivalent.",Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),[ng] / [ml],61.24,256021,DB00472,Fluoxetine
,17176627,Cmax,"The mean pharmacokinetic parameters for both of the drugs under study were as follows: Cmax = 61.24 (+/- 12.96) ng/ml for the test formulation, and for the reference formulation Cmax = 61.39 (+/- 14.1) ng/ml, the effects were statistically equivalent.",Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),[ng] / [ml],61.39,256022,DB00472,Fluoxetine
,17176627,tmax,The tmax for the test formulation was 8.25 (+/- 1.7) and 7.33 (+/- 0.96) for the reference formulation.,Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),,8.25,256023,DB00472,Fluoxetine
,17176627,tmax,The tmax for the test formulation was 8.25 (+/- 1.7) and 7.33 (+/- 0.96) for the reference formulation.,Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),,7.33,256024,DB00472,Fluoxetine
,17176627,area under the curve to infinity (AUC 0-infinity,"The area under the curve to infinity (AUC 0-infinity (ng, day/ml)) for the test formulation and for the reference formulation were 293.02 (+/- 52.69) and 296.15 (+/- 61.69), respectively.",Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),[d] / [ml],293.02,256025,DB00472,Fluoxetine
,17176627,area under the curve to infinity (AUC 0-infinity,"The area under the curve to infinity (AUC 0-infinity (ng, day/ml)) for the test formulation and for the reference formulation were 293.02 (+/- 52.69) and 296.15 (+/- 61.69), respectively.",Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),[d] / [ml],296.15,256026,DB00472,Fluoxetine
,17176627,relative bioavailability,"The two formulations had equivalent pharmacokinetic parameters, were well-tolerated, and their relative bioavailability was 98.94%.",Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176627/),%,98.94,256027,DB00472,Fluoxetine
,21308704,run time,A run time of 4 min means a high throughput of samples can be achieved.,Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308704/),min,4,256663,DB00472,Fluoxetine
,21877765,maximum plasma concentration (C(max)),"In the two periods of treatment, the mean maximum plasma concentration (C(max)) values were 817 ng/mL (lansoprazole alone) and 1370 ng/mL (lansoprazole in combination with fluoxetine after pre-treatment with fluoxetine for 8 days) [p < 0.0001].",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[ng] / [ml],817,260422,DB00472,Fluoxetine
,21877765,maximum plasma concentration (C(max)),"In the two periods of treatment, the mean maximum plasma concentration (C(max)) values were 817 ng/mL (lansoprazole alone) and 1370 ng/mL (lansoprazole in combination with fluoxetine after pre-treatment with fluoxetine for 8 days) [p < 0.0001].",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[ng] / [ml],1370,260423,DB00472,Fluoxetine
,21877765,area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],2400,260424,DB00472,Fluoxetine
,21877765,area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],6220,260425,DB00472,Fluoxetine
,21877765,AUC from time zero to infinity,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],2480,260426,DB00472,Fluoxetine
,21877765,AUC from time zero to infinity,"The observed area under the plasma concentration-time curve (AUC) from time zero to time of last measurable concentration values were 2400 and 6220 ng · h/mL (p < 0.0001), respectively, and the AUC from time zero to infinity values were 2480 and 7290 ng · h/mL (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),[h·ng] / [ml],7290,260427,DB00472,Fluoxetine
,21877765,time to reach C(max),"The time to reach C(max) values were 2.72 and 2.64 hours, respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,2.72,260428,DB00472,Fluoxetine
,21877765,time to reach C(max),"The time to reach C(max) values were 2.72 and 2.64 hours, respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,2.64,260429,DB00472,Fluoxetine
,21877765,elimination rate constant from the central compartment,"The elimination rate constant from the central compartment values were 0.50 and 0.21 h-1, respectively (p < 0.0001).",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),1/[h],0.50,260430,DB00472,Fluoxetine
,21877765,elimination rate constant from the central compartment,"The elimination rate constant from the central compartment values were 0.50 and 0.21 h-1, respectively (p < 0.0001).",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),1/[h],0.21,260431,DB00472,Fluoxetine
,21877765,elimination half-life,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,1.47,260432,DB00472,Fluoxetine
,21877765,elimination half-life,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,3.56,260433,DB00472,Fluoxetine
,21877765,mean residence times,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,4.0,260434,DB00472,Fluoxetine
,21877765,mean residence times,"The elimination half-life values were 1.47 and 3.56 hours (p < 0.0001), respectively, and the mean residence times were 4.0 and 6.9 hours (p < 0.0001), respectively.",Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877765/),h,6.9,260435,DB00472,Fluoxetine
,2320712,elimination half-lives (t1/2),"The mean elimination half-lives (t1/2) of FL and its active metabolite norfluoxetine (NFL) were about 5 and 15 h, respectively.",Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2320712/),h,5,263145,DB00472,Fluoxetine
,2320712,elimination half-lives (t1/2),"The mean elimination half-lives (t1/2) of FL and its active metabolite norfluoxetine (NFL) were about 5 and 15 h, respectively.",Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2320712/),h,15,263146,DB00472,Fluoxetine
,2320712,plasma protein binding,The mean blood:plasma concentration ratios of FL and NFL approached unity and plasma protein binding was 85-90% for both compounds.,Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2320712/),%,85-90,263147,DB00472,Fluoxetine
,2320712,extraction ratio,"At the lowest dose tested (5 mg/kg) the drug was efficiently extracted by the liver (extraction ratio about 60%), resulting in bioavailability of only about 38%.",Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2320712/),%,60,263148,DB00472,Fluoxetine
,2320712,bioavailability,"At the lowest dose tested (5 mg/kg) the drug was efficiently extracted by the liver (extraction ratio about 60%), resulting in bioavailability of only about 38%.",Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2320712/),%,38,263149,DB00472,Fluoxetine
,9433393,limits of q,"The assay limits of quantification were 0.1 ng/ml and 5.0 ng/ml, respectively.",Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433393/),[ng] / [ml],0.1,264133,DB00472,Fluoxetine
,9433393,limits of q,"The assay limits of quantification were 0.1 ng/ml and 5.0 ng/ml, respectively.",Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433393/),[ng] / [ml],5.0,264134,DB00472,Fluoxetine
,32649937,hepatic extraction,"PER is poorly to moderately metabolized (hepatic extraction = 0.2-0.7), while FLU is highly metabolized (hepatic extraction = 0.8-0.99).",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),,0.2-0.7,267441,DB00472,Fluoxetine
,32649937,hepatic extraction,"PER is poorly to moderately metabolized (hepatic extraction = 0.2-0.7), while FLU is highly metabolized (hepatic extraction = 0.8-0.99).",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),,0.8-0.99,267442,DB00472,Fluoxetine
,32649937,Vmax,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·min],90,267443,DB00472,Fluoxetine
,32649937,Vmax,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·min],16.4,267444,DB00472,Fluoxetine
,32649937,Vmax,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·min],86.1,267445,DB00472,Fluoxetine
,32649937,Vmax,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·min],16.9,267446,DB00472,Fluoxetine
,32649937,unbound Km,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,17,267447,DB00472,Fluoxetine
,32649937,unbound Km,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,1.7,267448,DB00472,Fluoxetine
,32649937,unbound Km,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,38.3,267449,DB00472,Fluoxetine
,32649937,unbound Km,"For the PER, the parameters were Vmax = 90, 16.4, 86.1 and 16.9 (nmol/min/g liver) and unbound Km = 17, 1.7, 38.3 and 1.4 (μM) for the scenarios WO, with ALB, with AGP and with MIX, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,1.4,267450,DB00472,Fluoxetine
,32649937,Vmax,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·liver·min],65.5,267451,DB00472,Fluoxetine
,32649937,Vmax,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·liver·min],18.5,267452,DB00472,Fluoxetine
,32649937,Vmax,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·liver·min],33.8,267453,DB00472,Fluoxetine
,32649937,Vmax,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),[nM] / [g·liver·min],12.2,267454,DB00472,Fluoxetine
,32649937,unbound Km,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,1.5,267455,DB00472,Fluoxetine
,32649937,unbound Km,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,0.03,267456,DB00472,Fluoxetine
,32649937,unbound Km,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,0.14,267457,DB00472,Fluoxetine
,32649937,unbound Km,"As for FLU, the parameters were Vmax = 65.5, 18.5, 33.8 and 12.2 (nmol/min/g liver) and unbound Km = 1.5, 0.03, 0.14 and 0.0466.31 (μM) in all four scenarios, respectively.",Impact of Extensive Plasma Protein Binding on the In Situ Hepatic Uptake and Clearance of Perampanel and Fluoxetine in Sprague Dawley Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649937/),μM,0.0466.31,267458,DB00472,Fluoxetine
,1424422,half-life,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),h,20,267843,DB00472,Fluoxetine
,1424422,half-life,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),h,17,267844,DB00472,Fluoxetine
,1424422,clearance,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),[ml] / [min],48,267845,DB00472,Fluoxetine
,1424422,clearance,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),[ml] / [min],61,267846,DB00472,Fluoxetine
,7963446,elimination half-life (t1/2),"Sertraline, and the starting dose of paroxetine have an elimination half-life (t1/2) of approximately 24 h.","Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270767,DB00472,Fluoxetine
,7963446,t1/2,At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),h,24,270768,DB00472,Fluoxetine
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,2-4,270769,DB00472,Fluoxetine
,7963446,t1/2,Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days.,"Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7963446/),d,7-15,270770,DB00472,Fluoxetine
,10950845,unbound plasma concentration,"Using the in vitro concentration-dependent rates for loss of activity, in vivo rates of CYP3A4 inactivation were predicted for these compounds at a clinically relevant unbound plasma concentration of 0.1 microM.",An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950845/),μM,0.1,271439,DB00472,Fluoxetine
,21757974,half-life,Fluoxetine had a half-life of 11-16 h and norfluoxetine had a half-life of 21-29 h.,Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757974/),h,11-16,272461,DB00472,Fluoxetine
,21757974,half-life,Fluoxetine had a half-life of 11-16 h and norfluoxetine had a half-life of 21-29 h.,Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757974/),h,21-29,272462,DB00472,Fluoxetine
